ESPOSITO, Carla
 Distribuzione geografica
Continente #
NA - Nord America 4314
EU - Europa 1266
AS - Asia 696
SA - Sud America 2
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 6280
Nazione #
US - Stati Uniti d'America 4278
UA - Ucraina 489
IT - Italia 447
CN - Cina 414
VN - Vietnam 210
DE - Germania 115
FI - Finlandia 99
SE - Svezia 64
TR - Turchia 62
FR - Francia 25
MX - Messico 24
RU - Federazione Russa 12
CA - Canada 11
GB - Regno Unito 8
IL - Israele 4
IN - India 3
BR - Brasile 2
IE - Irlanda 2
PH - Filippine 2
AL - Albania 1
AT - Austria 1
ES - Italia 1
EU - Europa 1
GR - Grecia 1
HN - Honduras 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
Totale 6280
Città #
Ann Arbor 1338
Wilmington 691
Jacksonville 595
Princeton 393
Houston 260
Chandler 254
Dong Ket 210
Woodbridge 209
Nanjing 110
Dearborn 107
Beijing 99
Andover 97
Pellezzano 76
Izmir 61
Salerno 60
Mestre 49
Fairfield 41
Redwood City 37
Nanchang 35
Hebei 33
Shenyang 33
Ashburn 31
Changsha 27
Tianjin 20
Jiaxing 19
Napoli 16
Sant'agata De' Goti 16
Cuauhtémoc 14
Agropoli 13
Norwalk 12
Cava 11
Düsseldorf 11
Ottawa 11
San Diego 11
Lessolo 9
Boardman 8
Spinea 8
Bari 7
Marsico Nuovo 6
Caserta 5
Hefei 5
Jinan 5
Cambridge 4
Dormagen 4
Kunming 4
Lequile 4
Phoenix 4
Seattle 4
Venezia 4
Zhengzhou 4
Buffalo 3
Falls Church 3
Ferrara 3
Guangzhou 3
Redmond 3
Renton 3
Trieste 3
Ariano Irpino 2
Fisciano 2
Florence 2
Haikou 2
Lanzhou 2
London 2
Maratea 2
Montemiletto 2
Naples 2
Nola 2
Portici 2
Reggio Calabria 2
Rome 2
Torre Del Greco 2
Vertova 2
Ballabio 1
Bracigliano 1
Castronno 1
Centro 1
Chengdu 1
Depew 1
Easton 1
Fuzhou 1
Genova 1
Hangzhou 1
Indiana 1
Istanbul 1
Lahore 1
Lecce 1
Macerata Campania 1
Madrid 1
Manocalzati 1
Menlo Park 1
Milan 1
Modugno 1
Monteforte Irpino 1
Montesarchio 1
Mumbai 1
New York 1
Nürnberg 1
Orange 1
Oslo 1
Pagani 1
Totale 5164
Nome #
Antibodies against type 2 transglutaminase modulate actin rearrangements and cell cycle in several cell lines 99
null 98
Synthesis of peptidocalix[4]arene diversomers as transglutaminase inhibitors by protein surface recognition 98
THE A-GLIADIN PEPTIDE 31-43 INDUCES NF-kB ACTIVATION AND MODULATE TYPE 2 TRANSGLUTAMINASE ACTIVITY IN AN INTESTINAL EPITHELIAL CELL LINE 96
Celiac anti‑type 2 transglutaminase antibodies induce differential effects in fibroblasts from celiac disease patients and from healthy subjects 95
Tissue transglutaminase in celiac disease: role of autoantibodies. 94
An acetic acid-based extraction method to obtain high quality collagen from archeological bone remains 94
Celiac anti-tissue transglutaminase antibodies interfere with the uptake of alpha gliadin peptide 31-43 but not of peptide 57-68 by epithelial cells 93
Celiac Disease-Specific TG2-Targeted Autoantibodies Inhibit Angiogenesis Ex Vivo and In Vivo in Mice by Interfering with Endothelial Cell Dynamics 93
Anti-tissue transglutaminase antibodies activate intracellular tissue transglutaminase by modulating cytosolic Ca(2+) homeostasis 91
Gliadin Peptides Induce Tissue Transglutaminase Activation and ER-Stress through Ca(2+) Mobilization in Caco-2 Cells. 91
Serum IgA and IgG and intestinal monoclonal anti-tissue transglutaminase antibodies from coeliac patients inhibit the catalytic activity both in vitro and in situ. 90
Enzymatic Strategies to Detoxify Gluten:Implications for Celiac Disease 90
4-Nonylphenol reduces cell viability and induces apoptosis and ER-stress in a human epithelial intestinal cell line 90
Anti-transglutaminase antibodies in non-coeliac children suffering from infectious diseases. 86
Application of a computational approach to identify protein targets for 4-nonylphenol 85
Celiac autoantibodies to tissue transglutaminase modulate alpha-gliadin peptide uptake by epithelial cells 84
Chronic Exposure to Cadmium Disrupts the Adrenal Gland Activity of the Newt Triturus carnifex (Amphibia, Urodela) 84
Expression and enzymatic activity of small intestinal tissue transglutaminase in coeliac disease 82
RhoB is associated with the anti-angiogenic effects of celiac patient transglutaminase 2-targeted autoantibodies. 82
Interaction of 'toxic' and 'immunogenic' A-gliadin peptides with a membrane-mimetic environment 81
Analysis of transglutaminase protein substrates by functional proteomics. 78
Tissue transglutaminase autoantibodies regulate actin rearrangements and cell cycle in several cell types 78
Internalization of alpha gliadin peptide 31-43 by Caco-2 cells does not require a surface receptor. 78
Transglutaminase 2 in celiac diasease: Minireview article 76
Mammalian Transglutaminases. Identification of substrates as a key to physiological function and physiopathological relevance. 76
Autoantibodies to tissue transglutaminase can induce ER (endoplasmic reticulum) stress response in Caco-2 cells 72
N-terminus end of rat prostate transglutaminase is responsible for its catalytic activity and GTP binding 72
null 71
New therapeutic strategies for coeliac disease: tissue transglutaminase as a target 71
The toxic alpha-gliadin peptide 31-43 enters cells without a surface membrane receptor 70
Anti-Tissue Transglutaminase Antibodies from Coeliac Patients Inhibit Transglutaminase Activity both in Vitro and in Situ 69
Tissue transglutaminase modulators regulate actin rearrangements and cell cycle in several cell types 69
ANTI-TISSUE TRANSGLUTAMINASE ANTIBODIES ACTIVATE CYTOSOLIC TISSUE TRANSGLUTAMINASE BY MOBILIZING CALCIUM IONS FROM INTRACELLULAR STORES 68
Celiac anti-type 2 transglutaminase antibodies induce phosphoproteome modification in intestinal epithelial Caco-2 cells 68
A-gliadin peptide 31-43 induces NF-κB and tissue transglutaminase activation in an intestinal epithelial cell line 67
Expression and Enzymatic Activity of Small Intestinal Tissue Transglutaminase in Coeliac Disease 66
Transglutaminase surface recognition by peptidocalix[4]arene diversomers. 65
Type 2 transglutaminase contributes to define a cellular phenotype typical of celiac cells. 65
Proteomics identification of acyl-acceptor and acyl-donor substrates for transglutaminase in a human intestinal epithelial cell line: implications for coeliac disease. 64
The surfactant 4-nonylphenol is cytotoxic for cells of the human gastrointestinal tract. 64
Influenza delle modifiche post-traduzionali sulle proprietà biologiche della TGasi presente nel secreto della ghiandola coagulatoria 62
Histological changes, apoptosis and metallothionein levels in Triturus carnifex (Amphibia, Urodela) exposed to environmental cadmium concentrations 62
Structural characterization of transglutaminase-catalyzed cross-linking between glyceraldehyde 3-phosphate deydrogenase and polyglutamine repeat. 62
Biochemical characterization of recombinant rat prostate transglutaminase expressed into MDCK cells 60
Anti-tissue transglutaminase antibodies have biological effects on cultured intestinal biopsies from celiac patients 60
A preliminary study on nonylphenol toxicity in human intestinal epithelial cells 60
Subcellular distribution of type 2 transglutaminase is constitutively different in skin derived-fibroblasts from celiac disease patients and from healthy controls 60
Tissue Transglutaminase and Coeliac Disease. 59
Seminal Vesicle Protein IV and Its Derived Active Peptides: A Possible Physiological Role in Seminal Clotting. 59
The monoclonal anti-tissue transglutaminase antibody CUB 7402 reduces the alpha-gliadin peptides uptake by Caco-2 cells 59
The Pituitary-adrenal gland Activity of Triturus carnifex (Amphibia, Urodela) exposed to Environmental Cadmium Concentrations 59
Tissue transglutaminase is implicated in the antiproliferative and proapoptotic effect induced by the histone deacetylase inhibitor 58
Studio del riconoscimento tra transglutaminasi di tipo 2 e auto-anticorpi anti-transglutaminasi caratteristici della malattia celiaca 58
Identification of differential phosphorylated proteins in Caco-2 cells treated with anti-tissue transglutaminase antibodies 58
GTPase and transglutaminase are associated in the secretion of rat anterior prostate. 57
Serum immunoglobulin A and G and monoclonal antibodies anti tissue-transglutaminase from coeliac patients inhibit the catalytic activity both in vitro and in situ. 57
Caratterizzazione della transglutaminasi da prostata di ratto espressa in cellule MDCK 56
Humoral immune response to tissue transglutaminase is related to epithelial cell proliferation in celiac disease. 56
Studi di specificità di isoforme dell'enzima transglutaminasi per modificare proteine del latte 55
Biological and immunological activities of serum anti-tissue transglutaminase antibodies from non-celiac subjects 55
Transglutaminase surface recognition by peptidocalix[4]arene diversomers 55
Transglutaminase-mediated amine incorporation into substance P protects the peptide against proteolysis in vitro. 53
Identification of acyl-acceptor and acyl-donor substrates for transglutaminase in CaCo-2 intestinal cell line: implications for coeliac disease 53
Role of type 2 transglutaminase autoantibodies in phatogenesis of celiac disease 53
Searching for the protein targets of 4-nonylphenol using a computational approach 53
Implication of cell-surface transglutaminase in gliadin peptides uptake by Caco-2 cells 52
Non celiac patients’ anti-tissue transglutaminase antibodies: immunological and functional characterization. 52
A-GLIADIN PEPTIDES INDUCE TISSUE TRANSGLUTAMINASE ACTIVATION THROUGH CA2+ MOBILIZATION IN CACO-2 CELLS 52
Implication of tissue transglutaminase and desmoplakin in cell adhesion mechanism in human epidermis 51
Transglutaminase-synthesized spermine derivative of substance P recognizes rat portal vein neurokinin-3 receptors. 51
Searching for the protein targets of 4-nonylphenol using a computational approach 51
Ubiquitination of tissue transglutaminase is modulated by interferon alpha in human lung cancer cells 50
Studies on transglutaminase type IV in relation to proteins occuring in rat coagulating gland secretion 49
Celiac anti-tissue transglutaminase autoantibodies interfere with the ability of alpha-gliadin peptide 31-43 to drive intestinal epithelial cells into S-phase. 49
Celiac anti-tissue transglutaminase antibodies derange alpha gliadin peptide 31-43 uptake by epithelial cells. 49
Riconoscimento di superficie delle transglutamminasi mediante diversomeri peptidocalix[4]arenici 48
Transglutaminase-synthesized analogs of substance P is a selective tool for neurokinin-2 receptors. 48
IgA e IgG sieriche e anticorpi monoclonali intestinali anti-transglutaminasi tissutale ottenuti da pazienti celiaci inibiscono l'attività catalitica sia in vitro che in situ 48
Anti-type 2 transglutaminase antibodies as modulators of type 2 transglutaminase functions: a possible pathological role in celiac disease 48
Substance P and its transglutaminase-synthesized spermine derivative elicit yawning behavior via nitric oxide in rats. 47
Desmoplakin acts as transglutaminase substrate in vitro. 46
Effects of Methyl Bromide on activity of blood coagulation enzymes 46
Protein SV-IV promotes nitric oxide production not associated with apoptosis in murine macrophages. 44
Characterisation of rat coagulating gland transglutaminase expressed in heterologous cell systems 42
Interaction of “toxic” and “immunogenic” A-gliadin peptides with a membrane-like environment in vitro. 42
Identification of tissue transglutaminase-reactive lysine residues in glyceraldheide-3-phosphate dehydrogenase 41
Tissue transglutaminase autoantibodies regulate actin rearrangements and cell cycle in several cell types. 41
Espressione e attività enzimatica della transglutaminasi tissutale nella mucosa intestinale di pazienti celiaci 41
Transglutaminase-mediated polyamination of vasoactive intestinal peptide (VIP) Gln16 residue modulates the VIP/PACAP receptor activity. 40
Enzymatic synthesis of vasoactive intestinal peptide analogs by transglutaminase. 39
Rat coagulating gland secretion contains a kinesin heavy chain-like protein acting as type IV transglutaminase substrate 38
Overlapping between fluorescence modifications and activation of prostate transglutaminase induced by sodium dodecylsulphate. 37
Expression and enzymatic activity of transglutaminase in the normal and coeliac small intestinal mucosa 37
Identification of tissue transglutaminase protein substrates in Caco-2 cells 37
Do tissue transglutaminase antibodies contribute to the intestinal lesion in celiac disease? 37
Rat prostate transglutaminase: biochemical properties of recombinant forms expressed into COS-1 cells 35
Serum IGA and IGG and intestinal monoclonal anti-tissue transglutaminase antibodies from coeliac patients inhibit the catalytic activity both in vitro and in situ. 34
Preparation and mechanical properties of edible pectin-soy flour films obtained in the absence or presence of transglutaminase. 33
Characterisation of duodenal transglutaminase in coeliac disease 33
Totale 6230
Categoria #
all - tutte 8384
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8384


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/2018704 0000 114136 7271 791129111
2018/2019591 40492159 43148 1927 3654887
2019/20201097 2665112011 11045 13714 1136513530
2020/2021986 5971075 13237 1129 13213115222
2021/2022769 0042 4013 125 11487121362
2022/2023398 13410331130 00 00 0000
Totale 6474